SINOMAB BIO-B(03681): Liang Fang resigns as Executive Director and Chief Operating Officer.

18:44 18/08/2026

China Antibody-B (03681) announced that Ms. Liang Fang has resigned from her position as Executive Director and Chief Operating Officer of the company, effective August 18, 2026, to devote more time to handling other personal matters. Following her resignation, Ms. Liang will no longer hold any position within the group.

SINOMAB BIO-B (03681) announced that Ms. Liang Fang has resigned as the companys executive director and chief operating officer, effective August 18, 2026, to devote more time to handling other personal affairs. Following her resignation, Ms. Liang will no longer hold any position within the group.

YUM CHINA (09987) repurchased 22,850 shares at a cost of approximately HKD 8.5133 million on August 17 at the Hong Kong Stock Exchange.

Policy dividends are being released at an accelerated pace! iFlytek Medical (02506) saw a 47.5% increase in revenue from AI diagnostic assistants in the first half of the year, with a market share exceeding 80% in the grassroots sector.

USAS BUILDING (02671) issued a profit warning, expecting a mid-term consolidated net profit of approximately 9.9 million yuan, a decrease of about 84.2% compared to the same period last year.

YUM CHINA (09987) repurchased 22,850 shares at a cost of approximately HKD 8.5133 million on August 17 at the Hong Kong Stock Exchange.

USAS BUILDING (02671) issued a profit warning, expecting a mid-term consolidated net profit of approximately 9.9 million yuan, a decrease of about 84.2% compared to the same period last year.